Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis) - Summary - MDSpire

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

  • By

  • Luciano Ibba

  • Sara Di Giulio

  • Piergiorgio Malagoli

  • Anna Balato

  • Angelo Valerio Marzano

  • Matteo Megna

  • Diego Orsini

  • Lidia Sacchelli

  • Santo Raffaele Mercuri

  • Emanuele Trovato

  • Serena Giacalone

  • Alexia Pedron

  • Marzia Caproni

  • Edoardo Cammarata

  • Aldo Cuccia

  • Andrea Altomare

  • Alexandra M. G. Brunasso

  • Valentina Dini

  • Simone Ribero

  • Nicola Zerbinati

  • Francesco Messina

  • Stefano Caccavale

  • Carlo G. Carrera

  • Luca Potestio

  • Viviana Lora

  • Andrea Carugno

  • Federico Bardazzi

  • Giovanni Paolino

  • Antonio Costanzo

  • Alessandra Narcisi

  • Mario Valenti

  • March 16, 2026

  • 0 min

Share

Objective:

To evaluate the effectiveness, impact on scalp involvement, and safety profile of deucravacitinib in patients with moderate-to-severe psoriasis treated for at least 16 weeks.

Key Findings:
  • Patients achieved significant improvements in psoriasis severity after 16 weeks, with further enhancements noted at 32 weeks.
  • Deucravacitinib demonstrated rapid and sustained effectiveness on scalp psoriasis.
Interpretation:

The study provides real-world evidence supporting the efficacy of deucravacitinib in treating moderate-to-severe psoriasis, particularly in challenging scalp areas.

Limitations:
  • Retrospective design may limit data completeness and reliability.
  • Missing data could not be recovered or retrieved.
Conclusion:

Deucravacitinib shows promising short-term efficacy and safety for patients with moderate-to-severe psoriasis, especially for scalp involvement.

Original Source(s)

Efficacy and Safety of Deucravacitinib for Psoriasis: A Multicenter Real-World Analysis Focusing on Scalp Outcomes—IL PSO (Italian Landscape Psoriasis)

  • by Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, Anna Balato, Angelo Valerio Marzano, Matteo Megna, Diego Orsini, Lidia Sacchelli, Santo Raffaele Mercuri, Emanuele Trovato, Serena Giacalone, Alexia Pedron, Marzia Caproni, Edoardo Cammarata, Aldo Cuccia, Andrea Altomare, Alexandra M. G. Brunasso, Valentina Dini, Simone Ribero, Nicola Zerbinati, Francesco Messina, Stefano Caccavale, Carlo G. Carrera, Luca Potestio, Viviana Lora, Andrea Carugno, Federico Bardazzi, Giovanni Paolino, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

  • March 16, 2026

Related Content

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness